Catalyst
Slingshot members are tracking this event:
BioPharmX Announces Final Phase 2a Trial Results Find BPX-01 Reduces Facial P. Acnes by More than 90% in Four Weeks
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BPMX |
|
|
||||
Additional Information
- BPX-01 significantly outperformed control vehicle- BPX-01 showed no detectable minocycline in bloodstream- Daily 10 mg dose of topical minocycline offered P. acnes reduction comparable to oral minocycline at 20 times the daily dose
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 22, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Minocycline, Bpx-01, Acne
